QIAGEN NV, Hilden, Germany, offers new insights into its next-generation sequencing (NGS) initiative, recently unveiling a sample-to-result NGS workflow at the Advances in Genome Biology and Technology (AGBT) meeting, which are designed to enable the routine use of this breakthrough technology beyond life sciences research in clinical diagnostics.

PeerSchatz QIAGEN copy
Peer M. Schatz

“We are pleased with the progress of our NGS initiative to create a complete portfolio of products and services to make this breakthrough technology more effective, robust, and scalable for areas such as clinical research and diagnostics,” says Peer M. Schatz, CEO, QIAGEN. “The development of our complete sample-to-result workflow is a key achievement in our initiative to offer a seamless integration of new NGS platforms with high-quality reagents, molecular testing content, and services.”

Dietrich Hauffe, PhD, senior vice president, life sciences business area, says the company is planning to begin placing NGS workflows with selected customer groups during 2013 and expects NGS to complement established molecular technologies, particularly real-time PCR. 

The company’s automated NGS workflow offers a streamlined and automated workflow built on components that include the following:

  • QIAcube® for fully automated nucleic acid isolation and purification, as well as library preparation.
  • New GeneReadDNAseq Target Enrichment gene panels designed for NGS applications based on the GeneGlobe® collection of more than 60,000 fully annotated molecular assays.
  • QIAcube NGS – a new QIAcube-based instrument for automated sequencing template preparation.
  • GeneReader – a new NGS benchtop sequencer that embraces many diagnostic workflow features and offers a high level of flexibility, scalability and efficiency.
  • A dedicated QIAGEN software solution for user-friendly and automated result analysis.

Click here to learn more.

[Source: QIAGEN]